Society of Urologic Oncology position statement: Redefining the management of hormone-refractory prostate carcinoma Journal Article
| Authors: | Chang, S. S.; Benson, M. C.; Campbell, S. C.; Crook, J.; Dreicer, R.; Evans, C. P.; Hall, M. C.; Higano, C.; Kelly, W. K.; Sartor, O.; Smith, J. A. Jr |
| Article Title: | Society of Urologic Oncology position statement: Redefining the management of hormone-refractory prostate carcinoma |
| Abstract: | Because patients with hormone-refractory prostate carcinoma are a very diverse group, management of these patients represents a unique challenge. Despite much research, to the authors' knowledge few studies published to date have provided definitive treatment answers. The Society of Urologic Oncology (SUO) convened a multidisciplinary panel of urologists, oncologists, and radiation oncologists to develop a treatment algorithm for patients with hormone-refractory prostate carcinoma. The resulting treatment outline was based on a review of the literature review and on the expert opinions of the panelists. The current article provided a logical progression of treatment choices that included hormonal manipulations, chemotherapeutic options, and adjunctive therapies. Future clinical trials and therapies were also discussed by the authors. Management strategies should be targeted toward the individual patient. Although significant progress has been made in understanding and treating hormone-refractory prostate carcinoma, earlier interventions would be ideal and better therapeutic approaches to prolong survival are necessary. © 2004 American Cancer Society. |
| Keywords: | cancer chemotherapy; androgen; prednisone; thalidomide; clinical trial; fatigue; review; cancer recurrence; bevacizumab; erlotinib; bone metastasis; cancer adjuvant therapy; cancer radiotherapy; antineoplastic agent; palliative care; prostate specific antigen; imatinib; unindexed drug; cancer immunotherapy; liver toxicity; bone marrow suppression; gastrointestinal symptom; estrogen; cyclophosphamide; dexamethasone; cancer pain; practice guideline; drug resistance, neoplasm; algorithms; docetaxel; cancer hormone therapy; prostatic neoplasms; leuprorelin; cancer vaccine; societies, medical; algorithm; thromboembolism; nonsteroid antiinflammatory agent; mitoxantrone; gefitinib; semaxanib; carcinoma; medical society; glucocorticoid; diethylstilbestrol; aminoglutethimide; antiandrogen; bicalutamide; flutamide; gonadorelin agonist; hydrocortisone; ketoconazole; nilutamide; orchiectomy; antineoplastic agents, hormonal; morphine; gynecomastia; testosterone; oblimersen; rapamycin; therapy; clinical trials; catheter ablation; zoledronic acid; prostate carcinoma; breast disease; cryotherapy; myopathy; androgen deprivation; lexidronam samarium sm 153; strontium 89; estramustine; glucose intolerance; hormone refractory; fosfestrol; ogx 011 |
| Journal Title: | Cancer |
| Volume: | 103 |
| Issue: | 1 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2005-01-01 |
| Start Page: | 11 |
| End Page: | 21 |
| Language: | English |
| DOI: | 10.1002/cncr.20726 |
| PUBMED: | 15558815 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 27" - "Export Date: 24 October 2012" - "CODEN: CANCA" - "Source: Scopus" |
